Septerna files for IPO on strength of preclinical data, vision for expanding GPCR landscape

Septerna is about to find out how a biotech without “any meaningful clinical data” fares in the late 2024 IPO market. The G protein-coupled receptor (GPCR) specialist is asking investors to fund development of its lead hypoparathyroidism candidate through phase 2 before it shares initial data in humans.